Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Optimizing Clinical Outcome and Toxicity in Lung Cancer Using a Genomic Marker of Radiosensitivity

View ORCID ProfileJacob G. Scott, Geoff Sedor, Michael W. Kattan, Jeffrey Peacock, G. Daniel Grass, Eric A. Mellon, Ram Thapa, Michael Schell, Anthony Waller, Sean Poppen, George Andl, Steven A. Eschrich, Thomas J. Dilling, William S. Dalton, Louis B. Harrison, Tim Fox, Javier F. Torres-Roca
doi: https://doi.org/10.1101/2020.01.09.20017046
Jacob G. Scott
1Departments of Translational Hematology and Oncology Research and Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Case Western Reserve University School Of Medicine, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jacob G. Scott
  • For correspondence: scottj10@ccf.org javier.torresroca@moffitt.org
Geoff Sedor
2Case Western Reserve University School Of Medicine, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael W. Kattan
3Department of Quantiative Health Sciences, Lerner Research Institiute, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Peacock
4Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Daniel Grass
4Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric A. Mellon
5Department of Radiation Oncology, University of Miami, Miami, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ram Thapa
6Department of Biostatistics, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Schell
6Department of Biostatistics, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Waller
7Varian Medical Systems, Palo Alto, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean Poppen
8Minnesota Twins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Andl
7Varian Medical Systems, Palo Alto, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Eschrich
6Department of Biostatistics, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas J. Dilling
4Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William S. Dalton
9DeBartolo Personalized Medicine Institute, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis B. Harrison
4Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Fox
7Varian Medical Systems, Palo Alto, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier F. Torres-Roca
3Department of Quantiative Health Sciences, Lerner Research Institiute, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: scottj10@ccf.org javier.torresroca@moffitt.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

While radiation therapy serves as the backbone for nearly 40% of all cancer cures, and is received by nearly 70% of all cancer patients at some point in their cancer journey, it has yet to enter the modern era of personalized medicine. While field shape and size is personalized anatomically for all patients, the dose of radiation is still prescribed in a one-size-fits-all manner. Given the reality of inter-tumoral heterogeneity demonstrated by cancer sequencing efforts, we propose that we are working under an outdated null hypothesis in our field: that all patients should respond the same to the same dose of radiation. We have previously developed a method by which to predict optimal dosing for a given patient, which we term the Genomically Adjusted Radiation Dose, given the a priori knowledge of a patient’s tumor genomics. Knowing how much dose a patient’s tumor requires for biological optimization provides the first opportunity to characterize the inefficienies of one-size-fits-all dosing schemes, that result in both over- and under-dosing for the majority of patients. To elucidate this inefficiency, and therefore the opportunity to improvement using a personalized dosing scheme, we develop a competing hazards-style mathematical model combining the canonical equations for tumor control and normal tissue complication probabilities. Using data from two prospectively collected cohorts of patients with non-small-cell lung cancer, we show how the results of a recent uniform dose escalation study can be explained by the biological innefficiency of empiric uniform dose escalation, and highlight the opportunities for improvement in radiation outcomes available today, without need for new technology or equipment.

Competing Interest Statement

JGS and JTR are co-inventors of and own IP for GARD and RxRSI. JTR and SE are co-inventors of and IP for RSI. JTR and SE have stock in Cvergenx. JGS has stock options in Cvergenx. TF, GA and AW have shared interest and stock in Varian Medical Systems.

Funding Statement

No external funding was received.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

NA

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 13, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Optimizing Clinical Outcome and Toxicity in Lung Cancer Using a Genomic Marker of Radiosensitivity
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Optimizing Clinical Outcome and Toxicity in Lung Cancer Using a Genomic Marker of Radiosensitivity
Jacob G. Scott, Geoff Sedor, Michael W. Kattan, Jeffrey Peacock, G. Daniel Grass, Eric A. Mellon, Ram Thapa, Michael Schell, Anthony Waller, Sean Poppen, George Andl, Steven A. Eschrich, Thomas J. Dilling, William S. Dalton, Louis B. Harrison, Tim Fox, Javier F. Torres-Roca
medRxiv 2020.01.09.20017046; doi: https://doi.org/10.1101/2020.01.09.20017046
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Optimizing Clinical Outcome and Toxicity in Lung Cancer Using a Genomic Marker of Radiosensitivity
Jacob G. Scott, Geoff Sedor, Michael W. Kattan, Jeffrey Peacock, G. Daniel Grass, Eric A. Mellon, Ram Thapa, Michael Schell, Anthony Waller, Sean Poppen, George Andl, Steven A. Eschrich, Thomas J. Dilling, William S. Dalton, Louis B. Harrison, Tim Fox, Javier F. Torres-Roca
medRxiv 2020.01.09.20017046; doi: https://doi.org/10.1101/2020.01.09.20017046

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9766)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1558)
  • Health Policy (735)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11641)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1176)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4655)
  • Radiology and Imaging (777)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)